Skip to main content

Henneman John B III

In the past year, 2 open-market purchase filings worth $134.6K and no sales.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
$134.6K
2 filings
Sold
–
0 filings
Net
+$134.6K
Bought minus sold
Companies
2
With open-market trades

Trades

Every Form 4 that lists Henneman John B III as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

OFIX Orthofix Medical Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 8, 2026 (view filing)May 71 dayHenneman John B IIIDirectorPPurchase+5.00K$12.26+$61.3K+5.8%90.8K after

ANIK Anika Therapeutics, Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 4, 2026 (view filing)May 13 daysHenneman John B IIIDirectorPPurchase+5.00K$14.66+$73.3K+10.0%54.9K after

APRE Aprea Therapeutics, Inc.

Director2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 14, 2024 (view filing)Mar 131 dayHenneman John B IIIDirectorPPurchase+6.86K$7.29+$50.0K+536.4%8.14K after
Mar 14, 2024 (view filing)Mar 131 dayHenneman John B IIIDirectorPPurchase+6.86K–––3.43K afterDerivative2 lots

RCM R1 RCM Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 9, 2023 (view filing)Aug 81 dayHenneman John B IIIDirectorSSale−50.0K$17.17−$858.5K−40.9%72.1K after